• Profile
Close

Low‐dose and long‐term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients

International Forum of Allergy & Rhinology Jul 30, 2020

Renteria AE, Maniakas A, Mfuna LE, et al. - Since it is suspected that the sinonasal microbiome plays an important role in the pathophysiology of refractory chronic rhinosinusitis (CRS), researchers assessed changes in the microbiome following a 4‐month course of low‐dose azithromycin. The assessment of microbiome alterations after such treatment can help to identify the underlying mechanisms of this drug. In total, 48 adults with refractory CRS were recruited. Study participants were randomized to 250 mg of azithromycin or placebo 3 times weekly for 4 months. According to this double‐blind, randomized, placebo‐controlled trial, a 4‐month 250 mg course of azithromycin 3 times weekly in patients with refractory CRS significantly reduces Staphylococcus aureus abundance in the sinonasal microbiome. Considering the pathogenic function of S. aureus in the refractory CRS population, azithromycin may provide an additional therapeutic choice to help control this disease.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay